文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

血清内皮细胞特异分子-1与降钙素原对脓毒症早期诊断及预后评估的临床价值

[Clinical value of serum endocan and procalcitonin in early diagnosis and prognosis evaluation of sepsis].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2017-01-01
一句话结论脓毒症患者血清内皮细胞特异分子-1诊断及预后评估价值可能优于降钙素原,诊断界值1.26 μg/L,死亡预测界值4.37 μg/L。

该研究纳入ICU的SIRS患者26例和脓毒症患者78例,按病情严重程度将脓毒症分为一般脓毒症组20例、严重脓毒症组24例和脓毒性休克组34例,按28天病死率分为存活组55例和死亡组23例。入住ICU时记录血清内皮细胞特异分子-1、降钙素原、APACHEII评分和SOFA评分。脓毒症组各指标及28天病死率均显著高于SIRS组,且随病情严重程度加重呈升高趋势。内皮细胞特异分子-1诊断脓毒症的AUC为0.887,预测死亡的AUC为0.915。作者认为血清内皮细胞特异分子-1在脓毒症早期诊断和预后评估中的临床价值优于降钙素原。

要点

  • 脓毒症组血清内皮细胞特异分子-1为4.28(10.64)μg/L,显著高于SIRS组的1.03(0.69)μg/L(P<0.01)。
  • 内皮细胞特异分子-1诊断脓毒症的AUC为0.887,界值1.26 μg/L时敏感度87.2%、特异度81.8%。
  • 降钙素原诊断脓毒症的AUC为0.842,界值0.75 μg/L时敏感度85.9%、特异度81.8%。
  • 内皮细胞特异分子-1预测脓毒症死亡的AUC为0.915,界值4.37 μg/L时敏感度95.7%、特异度70.9%。
  • 降钙素原预测脓毒症死亡的AUC为0.763,界值7.68 μg/L时敏感度65.2%、特异度78.2%。

适用人群与场景

  • 2014年12月至2016年12月河北医科大学第三医院ICU收治的SIRS患者(n=26)和脓毒症患者(n=78)。
  • 脓毒症患者按病情严重程度分为一般脓毒症组(n=20)、严重脓毒症组(n=24)和脓毒性休克组(n=34)。
  • 按28天病死率分为存活组(n=55)和死亡组(n=23)。

诊断标准与关键阈值

  • 脓毒症诊断界值:内皮细胞特异分子-1为1.26 μg/L时,敏感度87.2%、特异度81.8%。
  • 脓毒症诊断界值:降钙素原为0.75 μg/L时,敏感度85.9%、特异度81.8%。
  • 脓毒症死亡预测界值:内皮细胞特异分子-1为4.37 μg/L时,敏感度95.7%、特异度70.9%。
  • 脓毒症死亡预测界值:降钙素原为7.68 μg/L时,敏感度65.2%、特异度78.2%。

研究设计与关键结果

  • 研究类型为病例对照研究,纳入河北医科大学第三医院ICU的SIRS患者26例和脓毒症患者78例,入住ICU时记录血清内皮细胞特异分子-1、降钙素原、APACHEII评分和SOFA评分。
  • 脓毒症组vs SIRS组:内皮细胞特异分子-1为4.28(10.64)μg/L vs 1.03(0.69)μg/L,降钙素原为3.94(10.75)μg/L vs 0.43(0.39)μg/L,APACHEII评分为18.81±9.17 vs 9.35±3.78,SOFA评分为9.00(7.20)vs 4.50(1.50),28天病死率为29.49% vs 11.54%,均P<0.01。
  • 脓毒症诊断AUC:内皮细胞特异分子-1为0.887,降钙素原为0.842,APACHEII评分为0.822,SOFA评分为0.835。
  • 脓毒性休克组vs严重脓毒症组vs一般脓毒症组:内皮细胞特异分子-1为13.02(6.70)μg/L vs 3.33(3.05)μg/L vs 1.60(0.98)μg/L,降钙素原为8.10(17.68)μg/L vs 5.47(8.92)μg/L vs 1.57(2.78)μg/L,APACHEII评分为25.00(9.50)vs 18.00(9.00)vs 9.50(5.75),SOFA评分为13.00(4.50)vs 8.00(3.00)vs 5.00(3.50),28天病死率为52.94% vs 20.83% vs 0%,均P<0.01。
  • 内皮细胞特异分子-1、降钙素原、APACHEII评分、SOFA评分之间呈显著正相关。
  • 死亡组vs存活组:内皮细胞特异分子-1为15.05(9.23)μg/L vs 2.32(4.81)μg/L,降钙素原为18.40(16.99)μg/L vs 3.10(6.67)μg/L,APACHEII评分为28.13±7.56 vs 14.91±6.64,SOFA评分为14.70±3.65 vs 7.38±3.26,均P<0.01。
  • 死亡预测AUC:内皮细胞特异分子-1为0.915,降钙素原为0.763,APACHEII评分为0.899,SOFA评分为0.930。

证据类型、等级与局限

  • 证据类型:病例对照研究。
  • 作者结论:血清内皮细胞特异分子-1在脓毒症早期诊断和预后评估中的临床价值优于降钙素原。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为血清内皮细胞特异分子-1在脓毒症早期诊断和预后评估中的临床价值优于降钙素原。
  • 对ICU收治的SIRS和脓毒症患者,入住ICU时可同时记录血清内皮细胞特异分子-1、降钙素原、APACHEII评分和SOFA评分,用于病情严重程度和28天死亡风险的评估。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the clinical value of serum endocan and procalcitonin (PCT) in early diagnosis and prognosis evaluation of sepsis.

METHODS: The patients with systemic inflammatory response syndrome (SIRS, n = 26) and sepsis (n = 78) admitted to intensive care unit (ICU) of the Third Hospital of Hebei Medical University from December 2014 to December 2016 were enrolled. According to the severity of disease, the sepsis patients were divided into general sepsis group (n = 20), severe sepsis group (n = 24), and septic shock group (n = 34). The cases were divided into survival group (n = 55) and non-survival group (n = 23) according to 28-day mortality. The serum endocan, PCT, acute physiology and chronic health evaluation II (APACHEII) score, and sequential organ failure assessment (SOFA) score were recorded when the patients were admitted into ICU. The differences in endocan, PCT, APACHEII, SOFA score between SIRS and sepsis groups and within sepsis subgroups were compared. Spearman correlation analysis was used to analyze the correlation between the indexes of sepsis patients. Receiver operation characteristic curve (ROC) was used to evaluate the value of endocan and PCT for the diagnosis and prognosis of sepsis.

RESULTS: (1) Serum endocan, PCT, APACHEII, SOFA score and 28-day mortality in the sepsis group were significantly higher than those in the SIRS group [endocan (μg/L): 4.28 (10.64) vs. 1.03 (0.69), PCT (μg/L): 3.94 (10.75) vs. 0.43 (0.39), APACHEII: 18.81±9.17 vs. 9.35±3.78, SOFA: 9.00 (7.20) vs. 4.50 (1.50), 28-day mortality: 29.49% vs. 11.54%, all P < 0.01]. The area under the ROC curve (AUC) of endocan, PCT, APACHEII, SOFA score for sepsis diagnosis were 0.887, 0.842, 0.822, 0.835, respectively. When the cut-off value of endocan was 1.26 μg/L, the sepsis diagnostic sensitivity was 87.2% and specificity was 81.8%. When the cut-off value of PCT was 0.75 μg/L, the sepsis diagnostic sensitivity was 85.9% and specificity was 81.8%. (2) With the severity of the disease increased, the index showed an increasing trend in patients with sepsis. Serum endocan, PCT, APACHEII, SOFA score and 28-day mortality in septic shock group were significantly higher than those in severe sepsis group or general sepsis group [endocan (μg/L): 13.02 (6.70) vs. 3.33 (3.05), 1.60 (0.98); PCT (μg/L): 8.10 (17.68) vs. 5.47 (8.92), 1.57 (2.78); APACHEII: 25.00 (9.50) vs. 18.00 (9.00), 9.50 (5.75); SOFA: 13.00 (4.50) vs. 8.00 (3.00), 5.00 (3.50); 28-day mortality: 52.94% vs. 20.83%, 0%; all P < 0.01]. There was a significantly positive correlation between endocan, PCT, APACHEII, SOFA, indicating that the endocan and PCT can be used to assess the severity of sepsis. (3) Serum endocan, PCT, APACHEII and SOFA score in non-survival group were significantly higher than those in the survival group [endocan (μg/L): 15.05 (9.23) vs. 2.32 (4.81), PCT (μg/L): 18.40 (16.99) vs. 3.10 (6.67), APACHEII: 28.13±7.56 vs. 14.91±6.64, SOFA: 14.70±3.65 vs. 7.38±3.26, all P < 0.01]. The AUC of endocan, PCT, APACHEII, SOFA score for the prediction of non-survival sepsis were 0.915, 0.763, 0.899, 0.930. When the cut-off value of endocan was 4.37 μg/L, the septic death prediction sensitivity was 95.7% and specificity was 70.9%. When the cut-off value of PCT was 7.68 μg/L, the septic death prediction sensitivity was 65.2% and specificity was 78.2%.

CONCLUSIONS: Serum endocan is more clinically valuable than PCT in early diagnosis and prognosis assessment of sepsis.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zhao R, Dong S. [Clinical value of serum endocan and procalcitonin in early diagnosis and prognosis evaluation of sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28420465. doi:10.3760/cma.j.issn.2095-4352.2017.04.007

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。